Medicine 4.0: Self-Regulating Insulin for Diabetes

Introduction: Redefining Medical Frontiers

Imagine a medicine so sophisticated it adapts to the body’s needs in real time, acting as if it were aware of its environment. This level of complexity, once confined to the realm of science fiction, is becoming a reality. A groundbreaking development, thousands of years in the making, represents a potential cure for diabetes and marks the emergence of what some are calling medicine 4.0. This new era in healthcare is approaching a mastery of biology and chemistry that rivals the complexity of life itself.

Table of Contents:

Understanding Diabetes Through the Ages

The human struggle against diabetes spans millennia. Its first recorded appearance in medical history dates back to ancient Egypt around 1550 BCE. This early understanding, part of medicine’s version 1.0 phase, was deeply intertwined with spiritual beliefs and rudimentary observations.

Early Descriptions in Ancient Texts

One of the oldest medical texts known, the Ebers Papyrus (circa 1550 BCE), provides an early documented description of diabetes. It characterised the disease by the “great emptying of urine,” a phrase indicative of the early physicians’ descriptive approach based on observable symptoms. While they lacked knowledge of the underlying cause, they accurately observed its devastating effects: unquenchable thirst, dramatic weight loss, and eventual death. How did ancient physicians, with limited tools, manage to describe a disease so accurately based purely on observation?

Medicine 1.0: Spiritual and Herbal Approaches

In this initial phase of medicine, illness was often treated as much a spiritual problem as a physical one. Treatments involved combining herbal remedies with spiritual practices. Herbal approaches included substances like bitter gourd, oil of roses, broken red coral, and sweet almonds. These were frequently coupled with practices such as chanting mantras and meditation, intended to restore balance to the mind and body. Generally, these methods proved unsuccessful in effectively treating diabetes.

The Evolution of Treatment: Medicine 2.0

Even during ancient times, a shift began to occur, laying the groundwork for medicine 2.0. This phase saw doctors embracing more empirical study and record-keeping, moving towards natural remedies based on observation rather than purely spiritual interventions.

Empirical Observations and Recognition

Around 400 BCE, across the Indian subcontinent, physicians observed enough cases to recognise another unmistakable sign of diabetes: the sweetness of urine. They noted that ants were attracted to the urine of affected individuals due to its high sugar content, leading them to term the condition “honey urine disease.”

Crucially, they distinguished between two forms: an aggressive type often seen in younger individuals, typically fatal within weeks or months, and a less severe form affecting “heavy, wealthy people.” This differentiation, though a rudimentary demographic description, showed an early attempt to systematically understand who the disease affected. They had correctly identified what modern medicine classifies as Type 1 and Type 2 diabetes.

Early Lifestyle and Natural Remedies

Recognizing a link to larger individuals, their treatment approaches began to include exercise and specific diets. Diets sometimes included substances like wheat, grains, bones, and fish, or less appealing options such as green lead and earth. Some practitioners even prescribed diets of only raw meat or chalk, hoping to slow the body’s apparent decline. While many of these specific dietary prescriptions were ineffective, diet and lifestyle changes remain a cornerstone of diabetes management today, highlighting the enduring value of these early empirical observations.

Targeted Therapies: Medicine 3.0 and the Discovery of Insulin

Moving beyond general lifestyle changes and natural remedies, the true entry into medicine 3.0 came with the ability to command specific, targeted therapies aimed at addressing the underlying biological mechanisms of disease. For diabetes, this pivotal moment arrived in the late 19th and early 20th centuries.

Identifying the Pancreas’s Role

A critical breakthrough occurred in the late 19th century when German scientists discovered that removing the pancreas from dogs induced diabetes. This crucial finding sparked intense research to isolate the substance within the pancreas responsible for regulating glucose levels.

The Isolation of Insulin

This quest culminated in 1921 in a small laboratory in Toronto, Canada. Frederick Banting and Charles Best successfully extracted insulin from a cow’s pancreas. They administered this extract to diabetic dogs, resulting in an almost immediate and complete reversal of diabetes symptoms, a feat previously unimaginable.

First Human Application

The following year, in January 1922, the first human treatment took place. A 14-year-old boy received the insulin injection. Within minutes, he awoke from a lethargic state, regaining full consciousness. This moment must have felt miraculous. While not a perfect cure, insulin provided patients with their first real lifeline, enabling them to manage their condition and live longer, healthier lives. This era of medicine, Medicine 3.0, is defined by the ability to target specific biological components, often by binding to or blocking receptors, from penicillin disrupting bacterial cell walls to modern CAR T-cell therapies training immune cells to target cancer.

Limitations of Current Insulin Therapy

While artificial insulin has been revolutionary, it is not without limitations. Administering insulin requires careful management and poses inherent risks, primarily related to maintaining precise blood sugar levels. If insulin was discovered in 1921, why are patients still facing such difficult management challenges a century later?

Manual Monitoring and Dosing Challenges

Current insulin therapy requires patients to monitor their blood sugar meticulously and inject insulin multiple times daily. This manual process is challenging because the body’s natural glucose regulation is incredibly precise, maintaining levels within a narrow range (around 3 millimolar variation when working correctly).

Injecting insulin manually essentially puts patients on a “hard mode” of biological regulation. Imagine comparing manual insulin dosing to constantly monitoring and adjusting the fuel injection on your car by hand while driving – that’s the level of vigilance required.

Risks of Hypoglycemia and Hyperglycemia

Incorrect dosing carries significant risks. Injecting too little insulin leads to glucose levels remaining too high, above 7 millimolar when fasted, a state called hyperglycemia. Chronic hyperglycemia damages the eyes, nervous system, and, at extreme levels, can induce ketoacidosis and potentially death.

Conversely, injecting too much insulin is dangerous. It can cause glucose levels to crash below 4 millimolar, a state known as hypoglycemia. Mild symptoms include dizziness and irritability, while at more extreme levels, hypoglycemia can lead to coma and potentially death. The manual injection process and the narrow therapeutic window mean that patients constantly navigate the risk of over or underdosing.

Towards Self-Regulating Medicine: The Vision for Medicine 4.0

Given the challenges of manual insulin therapy, one cannot help but observe that nature’s own regulatory system is superior. This observation fuels the vision for medicine 4.0: creating treatments that are not merely engineered solutions requiring manual intervention, but are instead self-aware. The goal is a medicine capable of detecting physiological conditions, such as glucose concentration in the blood, and responding autonomously. Such a medicine would understand when it needs to be active or inactive and could change its form or function to meet the body’s needs without manual intervention.

Mimicking Nature’s Awareness

This concept approaches the idea of nanomachines or something closely resembling them – tiny, complex systems that can interact with the body’s environment intelligently. The goal is to create something that acts with a similar level of responsiveness and precision as natural biological processes. Building such a system presents significant scientific hurdles.

The Challenge of Glucose Recognition

A fundamental problem in designing a glucose-responsive medicine is the chemical similarity of glucose to other common molecules. To a chemist, glucose looks remarkably like fructose or sucrose and many other sugars. It even shares similarities with paracetamol.

This poses a major challenge: a medicine designed to respond to glucose must not accidentally trigger if other sugars or even common painkillers are present, which would lead to unpredictable and potentially dangerous outcomes.

Synthetic Lectins: A Chemical Foundation

Addressing the challenge of specific glucose recognition was a crucial step towards developing a self-regulating insulin. This work originated in university research, focusing on creating molecules that could mimic nature’s recognition capabilities.

Academic Research at the University of Bristol

Work at the chemistry department at the University of Bristol, led by Professor Tony Davis, focused on developing these synthetic lectins. These are artificially designed molecules created to replicate the natural ability of proteins (lectins) to recognize and bind to specific carbohydrate structures, such as glucose.

The Difficult Binding Challenge

Designing these molecules is an unbelievably difficult chemical challenge. The molecule must bind tightly and quickly to glucose, and importantly, only to glucose, avoiding similar molecules like fructose or paracetamol. Furthermore, it needed to not only bind but also release glucose; if it bound glucose permanently, it would simply remove glucose from the blood supply, which is not the desired therapeutic effect.

After many years of dedicated research, the team successfully produced primitive candidates for synthetic lectins that exhibited approximately the desired properties – the ability to bind and release glucose. While early, these molecules demonstrated the potential for specific glucose recognition needed for a responsive therapeutic agent.

Bridging the Gap: Academia to Application

After major academic breakthroughs like this, advancements often quiet down. This is partly because academic funding supports initial breakthroughs but not necessarily the extensive development required to make them useful. Industry often hesitates to step in at this early stage due to the significant work still needed and the risk of failure. Fortunately, in this case, a researcher from the Bristol lab recognized this gap and launched a startup in 2015 to drive the development forward, preventing the breakthrough from remaining solely an interesting research paper.

Designing a Smart Insulin Molecule

The challenge then became how to make this glucose-binding molecule useful as a medicine. The answer lay in integrating it with the very hormone used to treat diabetes: insulin.

Understanding Insulin Structure and Function

Standard insulin molecules have a long, thick central region and two long, flexible “arms.”

When these arms are free, insulin is active; it binds easily to its receptors in the body via a binding site located on the thicker part of the molecule. This binding triggers the body to store glucose in muscles and fat and reduces the liver’s production of glucose, lowering blood sugar levels.

The Breakthrough Concept: Linking Glucose Binding to Insulin Activity

The key idea was to link the flexibility of insulin’s arms to the presence or absence of glucose. If the two arms of insulin are connected, they block access to the insulin receptor’s binding site, essentially switching insulin off.

The innovative concept was to attach the newly developed synthetic glucose-binding molecule to one arm of insulin. To the other arm, a molecule similar to glucose, but not glucose itself (a glucoside), was attached. This glucoside would serve as a potential, but imperfect, binding target for the glucose-binding molecule.

The Mechanism: Self-Regulation Explained

This design leads to a self-regulating mechanism. When blood sugar is high, glucose is present in abundance. The glucose-binding molecule attached to the insulin arm will readily bind and release the abundant glucose, allowing the insulin arms to remain free. With its arms free, insulin can function normally, binding to its receptors and lowering blood sugar. However, if sugar levels fall, glucose becomes scarce. In the absence of glucose, the glucose-binding molecule will start to interact weakly with the glucoside attached to the other insulin arm.

These weak binding interactions pull the insulin arms together, blocking the insulin receptor’s binding site and deactivating the insulin. Should glucose levels rise again, glucose would outcompete the weak glucoside binding, causing the insulin arms to snap open and reactivating the molecule. This system would allow the smart insulin to automatically turn off when glucose levels are low, preventing dangerous hypoglycemia.

Collaboration, Refinement, and Validation

Developing this complex system required extensive work and resources. Recognizing the scale of the task, the team sought collaboration.

Partnering with Industry

Around 2018, the startup team partnered with Novo Nordisk, one of the largest suppliers of insulin globally. These conversations led to Novo Nordisk acquiring the startup and continuing the research collaboration. The majority of the chemistry team stayed on to work with Novo Nordisk.

Years of Further Work and Publication

Tuning the system took six years of further research and development within the collaboration. The team successfully produced a modified insulin molecule capable of self-regulation. This achievement was published in Nature. The molecule was given the designation NNC 2215.

A significant challenge was ensuring this self-regulating insulin would work correctly at physiological conditions in humans, specifically deactivating precisely below 4 millimolar of glucose to maintain healthy blood sugar levels.

In Vitro Receptor Affinity Studies

Researchers studied how NNC 2215 interacts with the insulin receptor in vitro, comparing its affinity to human insulin and a current clinically used form of long-acting basal insulin. Studies measured receptor binding across various glucose concentrations (20, 10, 5, 3, and 0 millimolar).

At high glucose (20 mM), all three systems demonstrated broadly similar binding responses. However, as glucose concentrations decreased, NNC 2215 showed a notable reduction in binding strength. At 0 mM glucose, NNC 2215’s binding was 12.5 times weaker compared to its binding at 20 mM, confirming the theorized glucose-dependent deactivation mechanism.

Demonstrating Self-Regulation in Animal Studies

To assess how this smart insulin behaved within a living body, the research team conducted studies in diabetic animals.

Simulating Real-World Conditions

In these studies, diabetic animals received a constant intravenous infusion of glucose to simulate the effect of a meal. Then, either standard insulin or NNC 2215 was administered to regulate blood sugar, mimicking a diabetic patient injecting insulin. The quantities of glucose and insulin were carefully tuned to maintain constant blood sugar levels.

Testing the Response to Falling Glucose

The critical test came when the glucose line was stopped, simulating the end of a meal. This action caused glucose levels in both populations to plummet. For the population receiving standard insulin, blood glucose levels dropped to dangerously low levels, reaching as low as 3 millimolar (hypoglycemia). Researchers had to intervene immediately by restarting the glucose supply to prevent harm to the animals.

Evidence of Automatic Deactivation with NNC 2215

In contrast, for the animals receiving NNC 2215, glucose levels dropped rapidly but then suddenly began to plateau at around 4.5 millimolar. Despite the continued administration of NNC 2215, the self-regulating insulin had automatically deactivated itself. This prevented further glucose absorption and successfully kept glucose levels within a healthy tolerance range.

This outcome demonstrated that NNC 2215 was capable of sensing its environment (glucose concentration) and adjusting its activity accordingly, preventing the dangerous hypoglycemic state observed with normal insulin.

The Broader Landscape of Medicine 4.0 and Beyond

The development of a self-regulating insulin like NNC 2215 is a significant step, but it is also part of a larger wave of innovation pushing the boundaries of medicine.

Beyond Diabetes: Other Smart Therapies

We are entering an era where other types of advanced medicines are reaching the market. Medicine 4.0 focuses on therapies that are not merely targeted but are responsive and adaptive to the body’s complex, dynamic environment. This includes cancer treatments designed to react to specific environmental cues, such as pH levels or temperature, ensuring they selectively damage cancer cells while sparing healthy tissue.

Examples from Existing Research

Other examples of this trend include sophisticated nanorobots capable of navigating within the body to deliver medicine precisely where needed. These advancements signify a move towards therapies that interact with the body in a more sophisticated, context-aware manner.

Looking Towards Medicine 5.0

Looking further ahead, Medicine 5.0 might involve even more profound interventions. One concept is the possibility of creating or regenerating biological organs within the human body that could produce therapeutic substances autonomously. More realistically, it could involve therapies that learn to regrow, regraft, or repopulate cells on damaged organs. Some work has already begun on attempts to regenerate the insulin-producing cells in the pancreas, although this research is still many years from practical application.

Innovation Ecosystem: From Labs to Life-Changing Therapies

Encouragingly, groundbreaking advancements like self-regulating insulin are increasingly originating outside of large pharmaceutical giants and big corporations.

University Labs as Innovation Hubs

These significant breakthroughs are often emerging directly from university laboratories. This represents a shift from the traditional perception of innovation primarily stemming from industry R&D departments. It moves beyond the idea of simply “tech bros dropping out of college” to start software companies; now, scientists completing advanced degrees are producing cutting-edge developments in areas like insulin, quantum computing, and new energy technologies.

Supporting Scientist Entrepreneurship

These innovations are fundamentally reshaping entire industries. Their origin in academic environments, where curiosity and discovery are paramount, highlights the importance of supporting scientific research and entrepreneurship. Bridging the gap between theoretical breakthroughs in university labs and their practical application requires specific support mechanisms, including funding. Supporting organizations that assist scientists with entrepreneurial skills and funding can help ensure that life-changing discoveries receive the resources they need to reach those who will benefit most.

Conclusion: A New Era in Medicine

The journey from ancient observations of diabetes to the development of a self-regulating insulin like NNC 2215 is a testament to thousands of years of human perseverance and scientific advancement. This innovation represents a culmination of effort towards producing a potentially more effective diabetes treatment, offering the potential to free patients from the constant burden and risks associated with manual insulin dosing. It firmly places us at the threshold of Medicine 4.0, where therapies are intelligent and responsive. While further refinement and clinical trials are needed before this specific technology is available for human use, its development signals a future where medicine is more precise, safer, and more integrated with the body’s natural processes.

What can you do?

Supporting the translation of scientific theory into actionable solutions is vital for driving future breakthroughs. If you are a scientist in a university lab working on innovative research and seeking support to move your work forward, resources may be available to help connect theory with practical application. Supporting organizations that assist scientists with entrepreneurial skills and funding can help ensure that life-changing discoveries receive the resources they need to reach those who will benefit most. Additionally, raising awareness about the importance of scientific funding and advocating for fair pricing of essential medicines are crucial steps to ensure that advancements in healthcare are accessible to all.

Disclaimer

This article discusses various terms related to diabetes, its treatment, and medical research. In this context:

• Diabetes: A chronic condition characterised by high levels of sugar (glucose) in the blood.
• Insulin: A hormone produced by the pancreas that regulates blood sugar levels. Artificial insulin is used as a treatment for diabetes.
• Fructose/Sucrose/Paracetamol: Other molecules mentioned for their chemical similarity to glucose, highlighting the challenge of specific recognition.
• Hypoglycemia: A state where blood sugar levels are too low (typically below 4 millimolar in this context).
• Hyperglycemia: A state where blood sugar levels are too high (typically above 7 millimolar when fasted in this context).
• mmol/L (millimolar): A unit used to measure the concentration of substances, like glucose, in the blood. It indicates the number of millimoles of a substance per liter of solution.
• Synthetic Lectins: Artificially designed molecules that mimic natural proteins in their ability to recognize and bind to specific carbohydrate structures.
• Glucoside: A molecule similar to glucose, used in the smart insulin design to interact with the glucose-binding molecule when glucose is scarce.
• NNC 2215: The specific designation given to the developed self-regulating insulin molecule.
• Receptor affinity: A measure of how strongly a molecule (like insulin) binds to its target receptor (like the insulin receptor) in the body.
• Basal insulin: A type of long-acting insulin designed to provide a steady level of insulin over many hours.
• Intravenous dose: Administering a substance directly into a vein.

Read more about how scientists had a conversation with Whales!!

Find out more about the AI solving the global Protein Folding Challenge!!